Cecelia Health announced today it has partnered with The Jaeb Center for Health Research (JCHR) to pilot a study to remotely onboard and support people using Continuous Glucose Monitors (CGM). The study is funded by The Leona M. and Harry B. Helmsley Charitable Trust.
The focus of the study is to demonstrate scaled initiation, persistence and data-driven guidance for patients using a continuous glucose monitor (CGM) device such as the Dexcom G6 or the Abbott Freestyle Libre. Data from the T1D Exchange (T1DX) registry shows that those who use a CGM have a lower A1C and decrease their risk for severe HYPO and DKA events by almost 40%.
“The health care industry today is failing when it comes to supporting people who use insulin to manage their glucose levels. People need access to the best technology available, and hands- down that is Continuous Glucose Monitoring (CGM)” said David Panzirer, Trustee of the Helmsley Charitable Trust, and a parent of two children with Type 1 diabetes. “Imagine the model evolving to include prescribing a CGM, onboarding, data interpretation, remote data monitoring, and eventually even adjusting insulin doses that can be titrated via a decision- support algorithm optimized for each individual by a Certified Diabetes Educator (CDE), under physician orders. This is how we all see the future and this pilot is the first step towards getting there.”
“We’re excited to work on this innovative project that will measure and publish results related to improved glycemic control for patients using a CGM”, said Dr. Roy Beck, Executive Director of the Jaeb Center for Health Research Foundation, “Our objective is to determine whether CGM can be effectively initiated by adults using insulin with online and remote training instead of clinic- based training and the impact on glycemic control. This initiative has the potential to provide tremendous innovation through proven models within the diabetes landscape."